How FDA Panelists Casting Doubt on Antidepressant Use During Pregnancy Could Lead to Devastating Outcomes for Mothers

By Nicole Amoyal Pensak PhD and Andrew Novick MD, PhD

At a meeting held by the Food and Drug Administration on July 21, 2025, a panel convened by the agency cast doubt on the safety of antidepressant medications called selective serotonin reuptake inhibitors, or SSRIs, in pregnancy.

Click on link to read more...